Myriad Genetics (NASDAQ: MYGN) appointed Raj Jampa as chief technology officer, effective June 1, 2026, according to a company statement.

As CTO, Jampa will oversee strategy and execution of Myriad's technology organization, including leveraging artificial intelligence to drive efficiency. The molecular diagnostic and precision medicine company said Jampa will focus on modernizing technology infrastructure and scaling AI capabilities.

Before joining Myriad Genetics, Jampa held senior technology leadership positions at Agilent Technologies, Exact Sciences and Genomic Health, where he led transformation initiatives across enterprise platforms and digital capabilities.

"Raj is a proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise," said Sam Raha, chief executive officer of Myriad Genetics.

Jampa said he plans to partner across the organization to modernize the technology foundation and deliver solutions for patients, providers and the business.

Myriad Genetics develops and commercializes molecular tests that assess disease risk and guide treatment decisions across medical specialties. The Salt Lake City-based company focuses on genetic insights that can improve patient care and support earlier disease detection.